drugset

drugset / Trial / NCT05670951

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

NCT05670951 ↗

Phase 3 Recruiting 360 enrolled Elgan Pharma Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Timeline

Start: 2025-02-27
Primary completion: 2027-11
Completion: 2029-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ELGN-2112	Protein / enzyme biologic	—	—

Indications